We show that TCL1 transgenic mice with B cell-specific ablation of Nfat2 display a significantly shorter life expectancy (201 vs. 325 days) and transformation to aggressive B cell lymphoma. Here, NFATC1 is linked to B-cell non-Hodgkin lymphoma.